Viking Capital Investment Offering- 90% Subscribed

Stewart's Mill Value Add Investment Offering

ATLANTA, GA / ACCESSWIRE / November 28, 2023 / Viking Capital is pleased to announce the overwhelming success of its latest investment opportunity, Stewart's Mill, a 188-unit Value-Add offering that is currently 90% subscribed, with the Reserve class nearly at full capacity.

The outlook for investors in Stewart's Mill is promising, with projected annualized returns (AAR) ranging from 16-18%. Moreover, a projected equity multiple of 1.8 to 2.0x underscores the robust potential of this acquisition. It is worth highlighting that the purchase price is a remarkable 17% below the market average, and a rate cap of 6.12% showcasing Viking Capital's strategic expertise.

Situated in the highly sought-after I-20 West submarket, Stewart's Mill provides residents with exceptional access to major job centers in Atlanta, including downtown Atlanta and the expansive Fulton Industrial Corridor. This prime location ensures a convenient commute for residents and economic stability for investors.

The acquisition of Stewart's Mill aligns seamlessly with Viking Capital's commitment to high-potential markets, especially considering Atlanta's 29-county Metropolitan Statistical Area ranking as the ninth-largest and one of the fastest-growing in the nation.

Viking Capital's vision for Stewart's Mill includes an extensive value-add renovation covering over 73% of the units. This strategic investment emphasizes Viking Capital's dedication to providing enhanced value, with the potential to achieve rental premiums exceeding $175 per unit.

To learn more about this investment offering see our deal details below:

https://vikingcapllc.investnext.com/portal/offerings/4578

Contact Information

Ashley Penrod
Director of Marketing
[email protected]
2088599720

SOURCE: Viking Capital

You May Also Be Interested In

• 'Chrysalis' Earns Strong Vietnam Response Ahead of April 2027 U.S. Premiere
• Canada and Norway strengthen defence cooperation through government-to-government procurement model
• AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib